DE60330966D1 - Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber - Google Patents

Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber

Info

Publication number
DE60330966D1
DE60330966D1 DE60330966T DE60330966T DE60330966D1 DE 60330966 D1 DE60330966 D1 DE 60330966D1 DE 60330966 T DE60330966 T DE 60330966T DE 60330966 T DE60330966 T DE 60330966T DE 60330966 D1 DE60330966 D1 DE 60330966D1
Authority
DE
Germany
Prior art keywords
imports
hemorrhagic fever
vesicular stomatitis
against viral
viral hemorrhagic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330966T
Other languages
German (de)
English (en)
Inventor
Steven Jones
Heinz Feldmann
Ute Stroeher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural Resources Canada
Original Assignee
Natural Resources Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60330966(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natural Resources Canada filed Critical Natural Resources Canada
Application granted granted Critical
Publication of DE60330966D1 publication Critical patent/DE60330966D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60330966T 2002-07-26 2003-07-28 Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber Expired - Lifetime DE60330966D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39855202P 2002-07-26 2002-07-26
PCT/CA2003/001125 WO2004011488A2 (en) 2002-07-26 2003-07-28 Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

Publications (1)

Publication Number Publication Date
DE60330966D1 true DE60330966D1 (de) 2010-03-04

Family

ID=31188416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330966T Expired - Lifetime DE60330966D1 (de) 2002-07-26 2003-07-28 Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber

Country Status (9)

Country Link
US (1) US8012489B2 (enExample)
EP (1) EP1527087B2 (enExample)
AT (1) ATE455124T1 (enExample)
AU (1) AU2003250680A1 (enExample)
CA (1) CA2493142C (enExample)
DE (1) DE60330966D1 (enExample)
ES (1) ES2338416T5 (enExample)
FR (1) FR20C1016I2 (enExample)
WO (1) WO2004011488A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116983A2 (en) * 2007-12-18 2009-09-24 Trustees Of Boston University Compositions and methods for treating ebola virus infection
US8796013B2 (en) 2007-12-18 2014-08-05 Trustees Of Boston University Pre-or post-exposure treatment for filovirus or arenavirus infection
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
KR101723900B1 (ko) 2009-06-08 2017-04-07 더 유니버시티 오브 웨스트 온타리오 면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형
US9402891B2 (en) * 2011-06-08 2016-08-02 Ohio State Innovation Foundation Norovirus immunogens and related materials and methods
US9474796B2 (en) 2012-08-14 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crimean-Congo hemorrhagic fever virus vaccine
US9795665B2 (en) 2012-08-14 2017-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
US20200181678A1 (en) * 2016-12-15 2020-06-11 Merck Sharp & Dohme Corp. Cell-Based Reporter Assay for Live Virus Vaccines
EP3681523A4 (en) * 2017-09-15 2021-12-29 The Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
TW202600150A (zh) 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
US11274282B2 (en) 2019-05-15 2022-03-15 Board Of Regents, The University Of Texas System Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
IL297237B2 (en) 2020-04-17 2025-08-01 Regeneron Pharma Detection assays for coronavirus neutralizing antibodies
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
CN117925662B (zh) * 2023-12-19 2024-08-13 军事科学院军事医学研究院军事兽医研究所 一种重组水泡性口炎病毒以及埃博拉出血热感染动物模型的构建方法
WO2025208054A1 (en) 2024-03-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Recombinant rhabdovirus encoding interleukin-12 (il-12)
CN120966775B (zh) * 2025-10-21 2026-02-03 浙江迪福润丝生物科技股份有限公司 一种携带马尔堡病毒缺陷型g蛋白的无神经毒性vsv载体重组溶瘤病毒

Also Published As

Publication number Publication date
ATE455124T1 (de) 2010-01-15
EP1527087A2 (en) 2005-05-04
WO2004011488A3 (en) 2004-04-15
FR20C1016I1 (enExample) 2020-06-12
ES2338416T3 (es) 2010-05-07
FR20C1016I2 (fr) 2022-04-01
CA2493142C (en) 2013-11-12
AU2003250680A1 (en) 2004-02-16
WO2004011488A2 (en) 2004-02-05
EP1527087B2 (en) 2013-07-17
CA2493142A1 (en) 2004-02-05
US8012489B2 (en) 2011-09-06
US20060193872A1 (en) 2006-08-31
AU2003250680A8 (en) 2004-02-16
EP1527087B1 (en) 2010-01-13
ES2338416T5 (es) 2013-11-20
WO2004011488A9 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
FR20C1016I2 (fr) Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales
DE60329367D1 (de) Verwendung bei der bekämpfung von hepatitis c virusinfektion
DE602004018284D1 (de) Mutante vesicular stomatitis viren und deren verwendungen
NO20044326D0 (no) Virale antigener
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DE60139127D1 (de) Von hepatitis c virus
DE69535018D1 (de) Papillomavirus vakzine
ATE309364T1 (de) Infektiöser cdna klon des das reproduktions- und atemwegs-syndrom verursachenden nord- amerikanischen schweinevirus und dessen verwendung
HRP20041085B1 (hr) Inhibitori hepatitis c virusa
DE60222841D1 (de) Keramische Matrix-Verbundwerkstoffe auf der Basis von Oxyde
EP0595436A3 (en) Swine virus, pathogen of the multiplying respiratory disease, vaccines and its viral DNA.
PL371007A1 (en) Macrocyclic peptides active against the hepatitis c virus
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
LU92749I2 (fr) Composition comprenant le virus de la diarrhée virale bovine atténué 1(bvdv-1) et le virus de la diarrhée virale bovine atténué 2 (bvdv-2)
DK1523329T3 (da) Viruspartikeladjuvant
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
FI913068A7 (fi) Ei-A-, ei-B-hepatiittiviruspartikkelit
FI910127A7 (fi) Ei-A-, ei-B-hepatiittiviruksen perimän cDNA ja antigeenipolypeptidi
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
AU2003294757A8 (en) Formulations useful against hepatitis c virus infections
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
WO2004039234A3 (en) Humanized antibodies against the venezuelan equine encephalitis virus
NO20024325D0 (no) Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse
NO20062384L (no) Anvendelse av BH4 for bahandling av respiratoriske sykdommer

Legal Events

Date Code Title Description
8363 Opposition against the patent